Respiratory, Cardiovascular and Metabolic Disease
Leveraging the high bioavailability of Bicycles as topical inhaled agents, in November 2016 Bicycle partnered with a world leader in respiratory science, AstraZeneca, to evaluate the potential for local delivery of inhaled Bicycles in the lung. In the same collaboration, AstraZeneca is evaluating Bicycles for the treatment of cardiovascular and metabolic diseases. AstraZeneca is using its therapy area expertise and access to significant resources to lead the optimization of Bicycles identified by the Bicycle® platform. In addition to the significant patient benefit that can result from leveraging the Bicycle® technology in these diseases, Bicycle can receive >$1B in milestone payments, as well as single digit royalties should all products reach the market. In May 2018, Bicycle and AstraZeneca expanded their collaboration to include additional targets in respiratory, cardiovascular and metabolic diseases. Two assets have been transitioned to AstraZeneca for further development and are currently being progressed in their discovery pipeline.